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Background: Tumor necrosis factor is an important mediator of lung transplant
acute rejection. Soluble type I tumor necrosis factor receptor binds to tumor necrosis
factor- and - and inhibits their function. The objectives of this study were to
demonstrate efficient in vivo gene transfer of a soluble type I tumor necrosis factor
receptor fusion protein (sTNF-RI-Ig) and determine its effects on lung allograft
acute rejection.
Methods: Three groups of Fischer rats (n  6 per group) underwent recipient
intramuscular transfection 24 hours before transplantation with saline, 1  1010
plaque-forming units of control adenovirus encoding -galactosidase, or 1  1010
plaque-forming units of adenovirus encoding human sTNF-RI-Ig (Ad.sTNF-RI-Ig).
One group (n  6) received recipient intramuscular transfection with 1  1010
Ad.sTNF-RI-Ig at the time of transplantation. Brown Norway donor lung grafts
were stored for 5 hours before orthotopic lung transplantation. Graft function and
rejection scores were assessed 5 days after transplantation. Time-dependent trans-
gene expression in muscle, serum, and lung grafts were evaluated by using enzyme-
linked immunosorbent assay of human soluble type I tumor necrosis factor receptor.
Results: Recipient intramuscular transfection with 1 1010 plaque-forming units of
Ad.sTNF-RI-Ig significantly improved arterial oxygenation when delivered 24
hours before transplantation compared with saline, -galactosidase, and Ad.sTNF-
RI-Ig transfection at the time of transplantation (435.8  106.6 mm Hg vs 142.3 
146.3 mm Hg, 177.4  153.7 mm Hg, and 237.3  185.2 mm Hg; P  .002, .005,
and .046, respectively). Transgene expression was time dependent, and there was a
trend toward lower vascular rejection scores (P .066) in the Ad.sTNF-RI-Ig group
transfected 24 hours before transplantation.
Conclusions: Recipient intramuscular Ad.sTNF-RI-Ig gene transfer improves allo-
graft function in a well-established model of acute rejection. Maximum benefit was
observed when transfection occurred 24 hours before transplantation.
Lung transplantation is an established treatment for a number ofend-stage pulmonary disorders.1 Unfortunately, ischemia-reperfu-sion injury and rejection continue to affect clinical lung transplan-tation.2 Our laboratory has demonstrated that gene transfer of trans-forming growth factor-1 and interleukin (IL)-10 reduces acuterejection in an experimental model of lung transplantation.3-5 These
studies illustrate that gene transfer of immunosuppressive cytokines may be useful
in reducing acute rejection in clinical lung transplantation.
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Tumor necrosis factor (TNF) is a proinflammatory cyto-
kine that mediates a variety of pathologic conditions.6 It is
primarily secreted by macrophages and influences the im-
mune response after organ transplantation.7,8 Soluble type I
TNF receptor (sTNF-RI) is a receptor for TNF- and -. It
has been identified in serum and urine.9 Soluble TNF-RI
and the cell-surface TNF receptor competitively bind to
TNF- and -. After sTNF-RI binds to TNF- and -, it
neutralizes their function.10 Therefore, gene transfer of
sTNF-RI-IgG fusion protein (sTNF-RI-Ig) has the potential
to reduce the immune response meditated by TNF and
ameliorate acute lung allograft rejection.
In vivo transgene expression with liposomal vectors to
introduce the chloramphenicol acetyl transferase reporter
gene into lung grafts has recently been examined. Chloram-
phenicol acetyl transferase expression was detected as early
as 2 hours after in vivo transfection, and it increased in a
time-dependent fashion.11 The delay between gene transfer
and gene expression is crucial for the success of cytokine
gene therapy in lung transplantation. In short, to reduce
acute rejection of lung allografts, gene expression needs to
occur before or during the acute lung injury. Experiments to
determine the influence of the timing of gene transfection on
the functional outcome of lung transplantation have not
been performed.
The aims of this study were to demonstrate efficient
adenovirus-mediated recipient sTNF-RI-Ig gene transfer,
determine its effect on lung allograft acute rejection, and
define the influence of the timing of gene transfection.
Materials and Methods
Animals
Fischer 344 rats and Brown Norway rats (Harlan Sprague Dawley
Inc, Indianapolis, Ind) weighing 250 to 280 g were used in all
experiments. The Animal Studies Committee at Washington Uni-
versity approved all animal procedures. Animals received humane
care in compliance with the Guide for the Care and Use of
Laboratory Animals prepared by the National Academy of Sci-
ences and published by the National Institutes of Health (National
Institutes of Health publication 85-23, revised 1985).
Adenoviral Vectors
Ad.sTNF-RI-Ig originates from a replication-deficient recombi-
nant type 5 adenovirus lacking the E1 and E3 loci.12 Soluble
TNF-RI-Ig complementary DNA was inserted in place of the E1
region, and expression was driven by the cytomegalovirus pro-
moter. Ad.sTNF-RI-Ig encodes a fusion protein that consists of the
extracellular domain of the human 55-kd TNF- receptor and the
CH2 through CH3 domains of a mouse immunoglobulin G1 heavy
chain.13 The adenovirus used in this study was provided as a gift
from Dr Paul D. Robbins, Departments of Molecular Genetics and
Biochemistry, University of Pittsburgh (Pittsburgh, Pa).14
The first-generation replication-deficient adenovirus serotype 5
carries the Escherichia coli LacZ gene. It is driven by the consti-
tutive cytomegalovirus promoter and encodes the enzyme -ga-
lactosidase. -Galactosidase is a nonfunctional reporter gene that
is used as an adenovirus control (provided by gene vector core,
University of North Carolina, Chapel Hill, NC).
Purified viral aliquots were stored at 70°C in 10% glycerol
buffered with 10 mmol/L Tris, 140 mmol/L NaCl, and 1 mmol/L
MgCl2. These stocks were thawed and diluted in sterile normal
saline solution immediately before use.
Experimental Design
Two experiments were performed in this study. Experiment 1
determined the time-dependent transgene expression of sTNF-RI-
Ig. Experiment 2 evaluated the effects of sTNF-RI-Ig gene trans-
fection on lung allograft acute rejection.
Experiment 1: Time-Dependent sTNF-RI-Ig
Expression in Muscle and Serum
Fischer 344 rats received transfection into the right gastrocnemius
muscle with 1  1010 plaque-forming units (pfu) of Ad.sTNF-RI-
Ig. Rats were killed 6, 12, 18, and 24 hours after transfection (n 
3 each) to determine sTNF-RI-Ig transgene expression in the right
gastrocnemius muscle and serum by using enzyme-linked immu-
nosorbent assay (ELISA).
Experiment 2: The Effects of sTNF-RI-Ig Gene
Transfection on Lung Allograft Acute Rejection
Fischer 344 rats were divided into 4 groups. Three groups (n  6
each) underwent recipient intramuscular transfection 24 hours
before transplantation with saline, 1  1010 pfu of control adeno-
virus encoding -galactosidase, or 1  1010 pfu of Ad.sTNF-RI-
Ig. One group (n  6) underwent recipient intramuscular trans-
fection with 1  1010 pfu of Ad.sTNF-RI-Ig at the time of
transplantation. Brown Norway donor lung grafts were stored for
5 hours before orthotopic lung allotransplantation. This combina-
tion of rats was chosen because of the strong major and minor
histocompatibility locus mismatch that results in complete lung
graft rejection within the fifth postoperative day in control recip-
ients without immunosuppression (Figure 1).
Recipient intramuscular gene transfer. Fischer 344 rats were
anesthetized with halothane. Adenovirus vector was dissolved in 1
mL of saline and injected into the right gastrocnemius muscle.
Figure 1. Experimental protocol. The experimental protocol was
separated by the vector and the timing of Ad.sTNF-RI-Ig transfec-
tion.
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Donor lung procurement. Brown Norway rats were anesthe-
tized with intraperitoneal pentobarbital (65 mg/kg), mechanically
ventilated, and heparinized (300 U), and a median laparosterno-
tomy was performed. Lungs were flushed through the main pul-
monary artery with 20 mL of cold (4°C) low-potassium dextran
glucose solution at 20 cm H2O pressure. The heart-lung block was
removed with the lungs inflated at end-inspiratory volume. The left
lung was isolated and stored at 4°C for 5 hours before implanta-
tion. The 5 hours of cold ischemia is consistent with cold ischemia
times in clinical transplantation.
Recipient animals were anesthetized and intubated with a 14-
gauge catheter, and a left thoracotomy was performed. The pul-
monary vessels and bronchus were dissected, and the lung graft
was anastomosed by using the modified cuff technique.15
Five days after transplantation, recipient animals were reanes-
thetized with pentobarbital. Animals were mechanically ventilated
via a tracheostomy with 100% oxygen. The right main bronchus
and pulmonary artery were clamped to isolate the left lung graft.
Animals were ventilated for 5 minutes at a tidal volume of 1.5 mL,
a respiratory rate of 100 breaths/min, and positive end-expiratory
pressure of 1.0 cm H2O. An arterial blood gas analysis was
performed, and the lungs were flushed with 20 mL of 4°C saline.
Left lung grafts were divided into 2 sections. The upper half was
used for histologic assessment of the rejection score. The lower
half was used for ELISA of human sTNF-RI, rat TNF-, IL-1,
IL-2, and interferon (IFN)-. Serum and transfected right gastroc-
nemius muscles from all rats were used for ELISA of human
sTNF-RI.
Histologic assessment of allograft rejection. Slides stained
with hematoxylin and eosin were reviewed by a blinded patholo-
gist (J.H.R.) with extensive experience reviewing rat and human
lung allograft rejection.3-5 Histologic rejection was graded on the
basis of the 1996 modification of the working formulation for the
classification of pulmonary allograft rejection.16 Vascular and
airway rejection were scored independently. A grade of 0 corre-
sponded to the absence of rejection, 1 to minimal rejection, 2 to
mild rejection, 3 to moderate rejection, and 4 to severe rejection
with complete allograft destruction. Vascular rejection was graded
as A0 to A4 and airway rejection as B0 to B4.
ELISA of sTNF-RI. Lung and muscle samples were homog-
enized with a lysis solution consisting of 100 mmol/L of potassium
phosphate dibasic, pH 7.8, including 0.2% Triton X-100 (Fisher
Scientific, Fair Lawn, NJ), 5 g/mL pepstatin A (Boehringer-
Mannheim, Indianapolis, Ind), and the protease inhibitor Complete
Mini (Roche, Inc, Nutley, NJ). After 15 minutes at room temper-
ature, the extraction was centrifuged at 11,000g for 10 minutes at
4°C. Serum samples were obtained by centrifugation of arterial
blood samples at 1000g for 10 minutes at 4°C. A human sTNF-RI
ELISA kit was used (R&D Systems Inc, Minneapolis, Minn).
There was no cross-reactivity between the human and rat sTNF-RI
proteins. Optical density was determined with an Ultra Microplate
Reader (EL808; Bio-Tek Instruments, Inc, Winooski, Vt) set to
450 nm. Total soluble protein (picograms per milligram of total
protein) was determined by the method of Pierce Laboratories
(Rockford, Ill).17
ELISA of rat TNF-, IL-1, IL-2, and IFN-. Reperfused
lung grafts from all 4 groups were used for ELISA of endogenous
rat TNF, IL-1, IL-2, and IFN-, as described previously for
sTNF-RI. The rat TNF, IL-1, IL-2, and IFN- ELISA kits were
purchased from R&D Systems.
Statistical Analysis
All values are presented as mean  SD. Data not normally
distributed were analyzed after logarithmic correction. One-way
analysis of variance with pairwise comparison by Fisher’s pro-
tected least significant difference was used to compare the differ-
ences among multiple groups.
Results
Experiment 1
Significant transgene expression of sTNF-RI-Ig was de-
tected in muscle and serum, and it increased in a time-
dependent fashion, with the maximum expression 24 hours
after transfection. The expression in muscle and serum 12,
18, and 24 hours after transfection was significantly higher
than the expression in both 6 hours after transfection (P 
.014, .015, and .002, respectively). The expression in serum
18 and 24 hours after transfection were also significantly
higher than 12 hours after transfection (P .011; Figure 2).
Experiment 2: Isolated Lung Allograft Gas Exchange
Intramuscular transfection of Ad.sTNF-RI-Ig 24 hours be-
fore transplantation significantly improved arterial oxygen
levels compared with saline, -galactosidase, and transfec-
tion of Ad.sTNF-RI-Ig at the time of transplantation (P 
.002, .005, and .046, respectively; Figure 3). There were no
significant differences in the mean carbon dioxide levels
among the 4 groups (P  .166).
Allograft Rejection Score
The vascular rejection scores for the saline, -galactosidase,
and Ad.sTNF-RI-Ig transfection 24 hours before transplan-
tation and Ad.sTNF-RI-Ig transfection at the time of trans-
plantation groups were 2.6  0.4, 2.8  0.5, 2.3  0.3, and
2.7  0.3, respectively. The vascular rejection score for the
Figure 2. Time-dependent expression of sTNF-RI-Ig after intra-
muscular transfection. The expression of sTNF-RI-Ig after trans-
fection with 1  1010 pfu of Ad.sTNF-RI-Ig into the right gastroc-
nemius muscle increased in a time-dependent manner in both
muscle and serum. *Values in these columns were significantly
lower than at the other times.
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Ad.sTNF-RI-Ig group transfected 24 hours before trans-
plantation was lower compared with the other 3 groups, but
this did not reach statistical significance (P  .066). There
were no significant differences in airway rejection scores
among the 4 groups (P  .836).
Soluble TNF-RI-Ig Expression 5 Days After
Transplantation
The extracts derived from muscle, lung, and serum 5 days
after transplantation were used for the measurement of
sTNF-RI ELISA. No transgene expression of sTNF-RI-Ig
was detected in the saline or -galactosidase control groups.
In both groups transfected with Ad.sTNF-RI-Ig, recipient
rats maintained strong expression of sTNF-RI-Ig in muscle.
When the sTNF-RI expression in serum and lung was
compared between recipient rats transfected 24 hours before
transplantation and those transfected at the time of trans-
plantation, the gene expression of sTNF-RI-Ig diminished
significantly from day 5 to day 6 after gene transfection (P
 .0001 for both; Figure 4).
Endogenous Rat TNF, IL-1, IL-2, and IFN- in
Allografts
The endogenous rat TNF, IL-1, IL-2, and IFN- levels in
transplanted lung allografts were measured to determine the
effect of sTNF-RI-Ig transfection on the production of these
cytokines. No significant differences were observed among
the 4 groups (P  .05).
Discussion
Acute rejection is one of the most important predictors of
postoperative morbidity and mortality after lung transplan-
tation.1,2 Conventional rescue therapy for acute rejection
uses anti-lymphocyte therapy and steroid pulse therapy, but
no definitive therapy has been established. The pathophys-
iology of acute rejection is complex, and numerous cyto-
kines affect the multifactorial rejection process.7
TNF is an important proinflammatory cytokine secreted
by mononuclear phagocytes and macrophages. It has been
broadly recognized for its pleiotropic effects on numerous
inflammatory and immunologic responses.18,19 It is impor-
tant to note that TNF plays a crucial role in inducing lung
transplantation acute rejection.7,8 TNF- and - promote
graft destruction by increasing the cytotoxicity of target
cells.7,20 Two kinds of TNF receptors, type I (p55) and type
II (p75), specifically bind TNF with equal affinity.21 These
soluble receptors are capable of neutralizing and modulating
the biological activity of TNF.9 This study evaluated the
ability of adenovirus-mediated gene transfer of sTNF-RI-Ig,
a TNF inhibitor, to reduce acute lung rejection.
We have recently demonstrated that adenovirus-medi-
ated TNF-inhibitor gene therapy ameliorates ischemia-
reperfusion injury in rat lung isografts.22 However, the
potential for TNF-inhibitor gene transfer to reduce acute
rejection had not been examined. In this study, in vivo
recipient intramuscular transfection with 1  1010 pfu of
Ad.sTNF-RI-Ig 24 hours before transplantation improved
isolated lung allograft oxygenation and showed a trend
Figure 3. Isolated lung allograft oxygenation 5 days after trans-
plantation. Five days after transplantation, the right hilum was
clamped, and the left lung was ventilated with 100% oxygen for
5 minutes. The allografts transfected with 1  1010 pfu of
Ad.sTNF-RI-Ig intramuscularly 24 hours before transplantation
had significantly superior arterial oxygenation (PaO2) compared
with the allografts transfected with saline, -galactosidase, and
1  1010 pfu of Ad.sTNF-RI-Ig at the time of transplantation.
Figure 4. Expression of sTNF-RI-Ig in muscle, lung, and serum 5
days after transplantation. In recipient rats transfected 24 hours
before transplantation, significant sTNF-RI-Ig transgene expres-
sion was observed in muscle, but less was observed in serum
and lung samples (6 days after transfection). In recipient rats
transfected at the time of transplantation with 1  1010 pfu of
Ad.sTNF-RI-Ig, higher transgene expression was observed in
muscle, serum, and lung samples (5 days after transfection).
*Values in these columns were significantly lower than those in
recipient rats transfected at the time of transplantation.
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toward decreased vascular rejection scores. Our ELISA data
demonstrate that adenovirus-mediated gene transfer of
sTNF-RI-Ig produces sTNF-RI protein in the muscle and
that it is released into the systemic circulation. Soluble
TNF-RI reaches the allograft, where it can bind endogenous
rat TNF and inhibit its cytotoxic effects.
The experimental group that received Ad.sTNF-RI-Ig at
the time of transplantation showed a trend toward improved
graft function but did not experience as dramatic an effect as
the group transfected 24 hours before transplantation. Our
ELISA data demonstrate that gene production after trans-
fection occurs in a time-dependent fashion and that the
values range in the order of muscle, serum, and lung. The
amount of sTNF-RI that reaches the lung allograft within
the first 12 hours in the group transfected at the time of
transplantation was not sufficient to reduce acute allograft
rejection in this experimental model. This may be partially
explained by an increased degree of ischemia-reperfusion
injury in the group transfected at the time of transplantation
because the sTNF-RI protein is not available for protection
at the time of transplantation.22 An alternative explanation
is that the sTNF-RI protein is not available at the time of
transplantation and thus does not ameliorate the early im-
munologic rejection process. Future work is required to
more fully explain the mechanism for this effect.
In localized transfection to the grafts, the organs in which
the gene product is being produced and in which the gene
product functions are the same. In the case of recipient
intramuscular transfection, they are different. For effect, in
vivo recipient intramuscular transfection requires gene
product being produced in muscle and released into the
circulation for an effect on the remote lung allograft.3,4,23
There are a number of possible advantages to intramuscular
transfection. The vector is easily administered. There also
may be an advantage in not introducing an inflammatory
adenoviral vector directly into the lung graft. In addition, it
would be relatively easy to treat the transplant recipient as
soon as a donor organ is identified.24-26 Furthermore, repet-
itive administration for sustained effect would be feasible in
immunosuppressed recipients.
In this study, serum and lung sTNF-RI ELISA data 5 and
6 days after transfection are difficult to explain. Despite
high expression in muscle at 6 days, serum and lung levels
of TNF-RI were low. The sTNF-RI used in this study was
of human—not rat—origin. It is possible that rat anti-
human sTNF-RI antibody bound the human sTNF-RI and
facilitated its elimination from the circulation. In the ab-
sence of a rat sTNF-RI gene, this speculation cannot be
addressed.
Although adenovirus sTNF-RI-Ig gene transfer dramat-
ically improved allograft function, it did not reduce the
airway rejection score or the endogenous inflammatory cy-
tokine milieu. There are a number of possible explanations
for this observation. The model used in this study is a major
mismatch combination that creates severe rejection and
graft loss within 5 days in untreated animals. The recipients
in this study received no immunosuppression. Also, inhibi-
tion of TNF action may help to improve lung graft function
without completely blocking the rejection cascade.17 Previ-
ous studies have demonstrated that the results of single
anticytokine therapy have been limited because of the over-
lapping activities of different cytokines.27 Combination
therapy directed toward the inhibition of several cytokines,
such as TNF and IFN-, may be more useful in improving
rejection scores and graft survival. Recent work by our
laboratory demonstrated that multiple genes can be co-
transfected.28 The co-transfection of Ad.sTNF-RI-Ig with
other anticytokine genes is an exciting area that requires
future investigation.
In conclusion, recipient intramuscular sTNF-RI-Ig gene
transfer improves allograft oxygenation and demonstrates a
trend toward a decreased vascular rejection score. The max-
imum benefit was observed when transfection occurred be-
fore transplantation. Recipient intramuscular delivery of
Ad.sTNF-RI-Ig is feasible and warrants further investiga-
tion to improve the outcome of clinical lung transplantation.
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Discussion
Dr Robert J. Korst (New York, NY). What was the rationale
for the intramuscular route as opposed to another route, such as
intravenous or something like that? With an intravenous route, you
probably could have saved a lot in terms of the quantity of vector
that you needed to use, or is there some downside of having it all
go to the liver: is there some downside of expressing that in the
liver, for example? What is the thinking behind the intramuscular
route?
Dr Alec Patterson (St Louis, Mo). It’s a good question. This
viral vector produces a certain inflammatory response by its ap-
plication, and we wanted to avoid any confounding effect that
might have on the subsequent rejection process. In previous work,
we demonstrated pretty good expression using the intramuscular
route, and that also has maybe the potential advantage of being
perhaps amenable to repetitive treatment. That is the rationale for
selection of the intramuscular route.
Dr Mark S. Allen (Rochester, Minn). Alec, did you look how
fast the gene gets incorporated? Because the one that you gave
right at the time of transplantation there didn’t seem to affect it, but
it did when you gave it some time before the transplant worked.
Does it take a couple hours or more than 12 hours to work? How
long before the transplantation do you have to give the gene before
it is effective?
Dr Patterson. I don’t know exactly what the ideal time is. I
know that it generally takes 12 to 24 hours. We reasoned that since
the inflammatory response of rejection was not likely going to be
maximal for a couple of days, transfection at the time of trans-
plantation might actually work. It wasn’t quite as good, but I think
maybe if it had been administered a few hours before transplan-
tation we might have seen some additional effects.
Dr Douglas E. Wood (Seattle, Wash). What do you think is the
best time to look at this? You chose 5 days in terms of looking at
the outcomes. Obviously, it is an evolving recipient. What do you
think is an advantage of 5 days versus looking at it maybe at 1 or
2 days or maybe looking at it even later and seeing what the more
chronic consequences are?
Dr Tagawa. In this major mismatched model, fulminant rejec-
tion is established at 5 days in control animals. This is the reason
we chose to kill animals at the 5-day point. It is quite possible that
there might have been a significant difference in results had the
analysis been made at 3 or 4 days, when the inflammatory response
is not so maximal. We have not conducted these experiments.
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